Evidence map›Paper›PMID 30864298›Full record

Observational studyGeriatrics & gerontology international2019

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.

Norifumi Tsuno, Takahiro Mori, Ichiro Ishikawa, Nobuyasu Bando, Haeyoung Park, Yoshito Matsumoto, Itsuko Mori, Mariko Tanaka, Takayuki Hirano, Yu Nakamura

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Geriatrics & gerontology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Norifumi TsunoDepartment of Neuropsychiatry, Faculty of Medicine, Kagawa University, Miki-cho, Japan.ORCID https://orcid.org/0000-0002-8174-3943
Takahiro MoriDepartment of Neuropsychiatry, Faculty of Medicine, Kagawa University, Miki-cho, Japan.
Ichiro IshikawaDepartment of Neuropsychiatry, Faculty of Medicine, Kagawa University, Miki-cho, Japan.
Nobuyasu BandoDepartment of Mental Health, Kaisei General Hospital, Sakaide, Japan.
Haeyoung ParkHarukaze Clinic, Chiba, Japan.
Yoshito MatsumotoNishitakamatsu Neurosurgery and Internal Medicine Clinic, Takamatsu, Japan.
Itsuko MoriMedical Juridical Person Eisei Hospital, Nakatado, Japan.
Mariko TanakaMino Tanaka Hospital, Miyoshi, Japan.
Takayuki HiranoZikeikai-Aoimori Hospital, Aomori, Japan.
Yu NakamuraDepartment of Neuropsychiatry, Faculty of Medicine, Kagawa University, Miki-cho, Japan.
Kagawa University · JPOsaka Kaisei Hospital · JPAomori Rosai Hospital · JPChiba Hospital · JPMiyoshi Kasei (Japan) · JPNational Hospital Organization Takamatsu Medical Center · JP

Funding

Ono Pharmaceutical
6 · The paper itself

Abstract

aimMost patients with Alzheimer's disease (AD) experience poor food intake and/or loss of appetite, which accelerates cognitive impairment. Several reports have shown that rivastigmine improves appetite in AD patients. The present study investigated the efficacy of a rivastigmine transdermal patch for the treatment of low food intake in AD patients.

methodsAD patients, recruited through the Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study, were recognized as experiencing either a loss of appetite or poor food intake. A rivastigmine transdermal patch was administered to study participants for 16 weeks. Patients' food intake, bodyweight, Mini-Mental State Examination scores and any adverse events were recorded.

resultsA total of 38 patients with AD (age 86.2 ± 5.4 years) were examined. Their mean Mini-Mental State Examination score was 10.1 ± 7.0 at baseline. A significant increase in food intake amount (54.9 ± 98.0 g, P < 0.01) and food intake ratio (9.3% ± 17.6%, P < 0.01) was observed by week 1, improvements that were maintained throughout the study duration. A multiple linear regression analysis showed that no independent variables were significantly associated with changes in food intake amount or ratio. Patients in the higher Mini-Mental State Examination subgroup showed a trend change in food intake amount, although this did not reach statistical significance (P = 0.07).

conclusionsThe present study suggests that a rivastigmine transdermal patch might improve poor food intake or loss of appetite in patients with AD. Geriatr Gerontol Int 2019; 19: 571-576.

Indexed as

Attitude to HealthEatingAged, 80 and overAlzheimer DiseaseAppetiteBody WeightCholinesterase InhibitorsCognitive DysfunctionFemaleHumansMaleMental Status and Dementia TestsRivastigmineSeverity of Illness IndexTransdermal PatchTreatment OutcomeCholinesterase InhibitorsRivastigmineAlzheimer's diseaseappetiterivastigminetransdermal patch

Identifiers

PMID30864298
PMCPMC6850597
OpenAlexW2921310131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.